A Phase 4 interventional study of Placebo and Adalimumab in Psoriasis, sponsored by Abbott. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-01.
Sponsored by Abbott · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 34th largest by enrollment, is one of 2 that started in 2008, is one of 11 in phase 4, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one is the 12th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2008, is the only one in phase 4, and was the 13th registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15. In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
Biological: Placebo · Biological: Adalimumab
80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
Biological: Adalimumab
Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
Also known as: Humira, ABT-D2E7
Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling) at Week 16. The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
Time frame: Week 16
Mean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the two soles and two palms, for a total range from 0 (no disease) to 48 points (most severe condition). A decrease from Baseline in ESIF indicates improvement.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Mean Change From Baseline in ESIF for Palms
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the palms of the hands, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the palms. A decrease from Baseline in ESIF indicates improvement.
Time frame: Baseline and Weeks 2, 4, 12, 16, 20, 24, and 28
Mean Change From Baseline in ESIF for Soles
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the soles of the feet, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the soles. A decrease from Baseline in ESIF indicates improvement.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Number of Subjects With Moderate Improvement in ESIF From Baseline
Number of subjects that achieved \> 50% reduction from Baseline in ESIF.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Number of Subjects With Marked Improvement in ESIF From Baseline
Number of subjects that achieved \> 75% reduction from Baseline in ESIF
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 28
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
For subjects with psoriasis nail involvement at Baseline, the target fingernail (most severely involved fingernail at Baseline) was assessed for NAPSI throughout the study. NAPSI ranges from 0 (no nail psoriasis) to 8 (most severe nail psoriasis).
Time frame: Baseline and Weeks 8, 16, and 28
Number of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis), almost clear (representing just perceptible erythema and scaling), or mild (representing light pink erythema with minimal scaling and with or without pustules). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28
Number of Subjects With PGA of Clear or Almost Clear
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
Time frame: Baseline and Weeks 2, 4, 8, 12, 20, 24, and 28
Number of Subjects With PGA of Clear
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, and 28
Number of Subjects With Psoriasis Area and Severity Index (PASI) 50
Number of subjects who achieved 50% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
Time frame: Baseline and Weeks 16 and 28
Number of Subjects With PASI 75
Number of subjects who achieved 75% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
Time frame: Baseline and Weeks 16 and 28
Number of Subjects With PASI 90
Number of subjects who achieved 90% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
Time frame: Baseline and Weeks 16 and 28
Number of Subjects With PASI 100
Number of subjects who achieved 100% improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
Time frame: Baseline and Weeks 16 and 28
Mean Change From Baseline in Dermatology Life Quality Index (DLQI)
The DLQI consists of 10 questions and is scored from 0 (total lack of impairment) to 30 (life is very much impaired). A decrease in DLQI indicates improvement.
Time frame: Baseline and Weeks 2, 8, 16, and 28
Number of Subjects Achieving a DLQI of 0
Number of subjects achieving a DLQI score of 0, indicating total lack of impairment. The DLQI consists of 10 questions and is scored from 0 to 30 (life is very much impaired). A decrease in DLQI indicates improvement.
Time frame: Baseline and Weeks 2, 8, 16, and 28
Mean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain
On one single VAS, subjects assessed their pain due to psoriasis (and psoriatic arthritis, if applicable). Mean change in psoriasis and psoriatic arthritis pain from Baseline as measured by a VAS from 0 (no pain) to 100 (pain as bad as it could be).
Time frame: Baseline and Weeks 16 and 28
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)
WPAI:PSO assesses the effect on the subject's ability to work and perform regular activities in 4 areas: % work time (in hours) missed due to psoriasis, % impairment while working (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), % overall work impairment (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), and % activity impairment (on a scale from 0 \[psoriasis having no effect on daily activities\] to 10 \[psoriasis completely prevented subject from doing daily activities\]).
Time frame: Baseline and Weeks 8, 16, and 28
Mean Change From Baseline in Patient Health Questionnaire (PHQ-9)
The PHQ-9 consists of 9 questions that assess how often over the past 2 weeks subjects had signs or symptoms of depression (0=not at all, 1=several days, 2=more than half days, and 3=nearly every day). The PHQ-9 is the sum of the scores from the 9 questions for a total range from 0 (not depressed at all) to 27 (depressed nearly every day).
Time frame: Baseline and Weeks 2, 8, 16, and 28
Number of Subjects With Difficulties According to PHQ-9
Based on the 9 questions of the PHQ-9, if subjects indicated any problems (PHQ-9 score \> 0), the difficulty to do work, take care of things at home, and get along with people (question 10 of the PHQ) were assessed (not difficult at all, somewhat difficult, very difficult, and extremely difficult).
Time frame: Baseline and Weeks 2, 8, 16, and 28
| Milestone | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Started | 23 | 49 |
| Completed | 17 | 41 |
| Not completed | 6 | 8 |
| Milestone | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Started | 18 | 41 |
| Completed | 13 | 40 |
| Not completed | 5 | 1 |
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling) at Week 16. The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16 | 1 | 15 |
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the two soles and two palms, for a total range from 0 (no disease) to 48 points (most severe condition). A decrease from Baseline in ESIF indicates improvement.
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | -2.35 ± 4.074 | -6.24 ± 7.685 |
| Week 4 | -1.91 ± 7.019 | -7.73 ± 9.064 |
| Week 8 | -3.04 ± 7.327 | -9.33 ± 9.335 |
| Week 12 | -5.30 ± 6.825 | -10.80 ± 11.175 |
| Week 16 | -5.04 ± 6.568 | -10.92 ± 12.460 |
| Week 20 (open-label) | -6.43 ± 8.805 | -11.69 ± 11.353 |
| Week 24 (open-label) | -5.83 ± 9.267 | -11.51 ± 11.502 |
| Week 28 (open-label) | -5.83 ± 8.574 | -11.96 ± 10.261 |
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the palms of the hands, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the palms. A decrease from Baseline in ESIF indicates improvement.
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | -1.78 ± 3.464 | -3.33 ± 4.095 |
| Week 4 | -1.57 ± 4.326 | -4.33 ± 4.543 |
| Week 8 | -2.09 ± 4.889 | -5.35 ± 4.829 |
| Week 12 | -3.39 ± 4.639 | -5.53 ± 5.934 |
| Week 16 | -2.65 ± 4.914 | -5.80 ± 6.285 |
| Week 20 (open-label) | -3.87 ± 5.810 | -6.16 ± 5.669 |
| Week 24 (open-label) | -3.74 ± 5.387 | -6.08 ± 5.947 |
| Week 28 (open-label) | -3.52 ± 4.870 | -6.59 ± 5.244 |
Severity of each sign of ESIF was assessed using a 4-point scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). The ESIF was calculated by adding the scores for the 4 signs for the soles of the feet, yielding a total range from 0 (no disease) to 24 points (most severe condition) for the soles. A decrease from Baseline in ESIF indicates improvement.
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | -0.57 ± 1.619 | -2.92 ± 4.650 |
| Week 4 | -0.35 ± 3.915 | -3.39 ± 5.553 |
| Week 8 | -0.96 ± 4.017 | -4.04 ± 5.972 |
| Week 12 | -1.91 ± 3.965 | -5.35 ± 6.515 |
| Week 16 | -2.39 ± 4.620 | -5.18 ± 7.132 |
| Week 20 (open-label) | -2.57 ± 5.358 | -5.47 ± 6.959 |
| Week 24 (open-label) | -2.09 ± 5.608 | -5.37 ± 7.082 |
| Week 28 (open-label) | -2.30 ± 5.431 | -5.31 ± 6.378 |
Number of subjects that achieved \> 50% reduction from Baseline in ESIF.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 1 | 8 |
| Week 4 | 2 | 10 |
| Week 8 | 3 | 17 |
| Week 12 | 6 | 20 |
| Week 16 | 4 | 21 |
| Week 20 (open-label) | 6 | 19 |
| Week 24 (open-label) | 6 | 21 |
| Week 28 (open-label) | 3 | 19 |
Number of subjects that achieved \> 75% reduction from Baseline in ESIF
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 0 | 3 |
| Week 4 | 0 | 5 |
| Week 8 | 0 | 7 |
| Week 12 | 0 | 11 |
| Week 16 | 1 | 14 |
| Week 20 (open-label) | 5 | 13 |
| Week 24 (open-label) | 4 | 12 |
| Week 28 (open-label) | 2 | 11 |
For subjects with psoriasis nail involvement at Baseline, the target fingernail (most severely involved fingernail at Baseline) was assessed for NAPSI throughout the study. NAPSI ranges from 0 (no nail psoriasis) to 8 (most severe nail psoriasis).
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 8 | -0.63 ± 1.061 | -0.88 ± 1.211 |
| Week 16 | -0.13 ± 1.246 | -1.67 ± 1.593 |
| Week 28 (open-label) | -1.00 ± 1.852 | -2.00 ± 2.177 |
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis), almost clear (representing just perceptible erythema and scaling), or mild (representing light pink erythema with minimal scaling and with or without pustules). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 2 | 15 |
| Week 4 | 3 | 21 |
| Week 8 | 6 | 21 |
| Week 12 | 8 | 24 |
| Week 16 | 6 | 25 |
| Week 20 (open-label) | 8 | 23 |
| Week 24 (open-label) | 7 | 20 |
| Week 28 (open-label) | 4 | 23 |
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 1 | 4 |
| Week 4 | 1 | 10 |
| Week 8 | 2 | 12 |
| Week 12 | 3 | 14 |
| Week 20 (open-label) | 5 | 11 |
| Week 24 (open-label) | 5 | 12 |
| Week 28 (open-label) | 2 | 12 |
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis). The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 0 | 1 |
| Week 4 | 0 | 2 |
| Week 8 | 0 | 3 |
| Week 12 | 0 | 6 |
| Week 16 | 1 | 6 |
| Week 20 (open-label) | 2 | 8 |
| Week 24 (open-label) | 3 | 7 |
| Week 28 (open-label) | 2 | 7 |
Number of subjects who achieved 50% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 16 | 5 | 21 |
| Week 28 (open-label) | 8 | 21 |
Number of subjects who achieved 75% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 16 | 2 | 15 |
| Week 28 (open-label) | 4 | 11 |
Number of subjects who achieved 90% or greater improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 16 | 0 | 10 |
| Week 28 (open-label) | 4 | 10 |
Number of subjects who achieved 100% improvement from baseline PASI. The PASI scale is from 0 (no psoriasis) to 72 (complete erythroderma of the severest possible degree).
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 16 | 0 | 7 |
| Week 28 (open-label) | 1 | 8 |
The DLQI consists of 10 questions and is scored from 0 (total lack of impairment) to 30 (life is very much impaired). A decrease in DLQI indicates improvement.
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | -3.43 ± 3.435 | -4.35 ± 4.741 |
| Week 8 | -3.09 ± 5.008 | -4.08 ± 5.541 |
| Week 16 | -4.22 ± 4.936 | -4.78 ± 7.269 |
| Week 28 (open-label) | -4.74 ± 4.731 | -5.18 ± 7.499 |
Number of subjects achieving a DLQI score of 0, indicating total lack of impairment. The DLQI consists of 10 questions and is scored from 0 to 30 (life is very much impaired). A decrease in DLQI indicates improvement.
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | 1 | 3 |
| Week 8 | 1 | 3 |
| Week 16 | 0 | 7 |
| Week 28 (open-label) | 1 | 6 |
On one single VAS, subjects assessed their pain due to psoriasis (and psoriatic arthritis, if applicable). Mean change in psoriasis and psoriatic arthritis pain from Baseline as measured by a VAS from 0 (no pain) to 100 (pain as bad as it could be).
| mm on scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 16 | -12.45 ± 28.637 | -17.49 ± 34.451 |
| Week 28 (open-label) | -16.25 ± 24.950 | -16.59 ± 34.430 |
WPAI:PSO assesses the effect on the subject's ability to work and perform regular activities in 4 areas: % work time (in hours) missed due to psoriasis, % impairment while working (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), % overall work impairment (on a scale from 0 \[psoriasis having no effect\] to 10 \[psoriasis completely prevented subject from working\]), and % activity impairment (on a scale from 0 \[psoriasis having no effect on daily activities\] to 10 \[psoriasis completely prevented subject from doing daily activities\]).
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| % Work Time Missed due to Psoriasis Week 8 | 6.32 ± 24.953 | 4.70 ± 12.778 |
| % Work Time Missed due to Psoriasis Week 16 | 7.72 ± 33.299 | 5.34 ± 20.250 |
| % Work Time Missed due to Psoriasis Week 28 (OL) | 2.60 ± 26.628 | 3.16 ± 18.198 |
| % Impairment While Working Week 8 | 0.71 ± 29.733 | -8.21 ± 27.087 |
| % Impairment While Working Week 16 | -4.67 ± 20.656 | -5.94 ± 27.103 |
| % Impairment While Working Week 28 (OL) | -5.33 ± 20.999 | -8.44 ± 31.429 |
| % Overall Work Impairment Week 8 | -0.48 ± 29.988 | -8.97 ± 27.355 |
| % Overall Work Impairment Week 16 | -5.45 ± 22.432 | -7.19 ± 26.556 |
| % Overall Work Impairment Week 28 (OL) | -5.79 ± 20.996 | -9.88 ± 31.045 |
| % Activity Impairment Week 8 | -9.09 ± 32.500 | -11.02 ± 23.562 |
| % Activity Impairment Week 16 | -9.09 ± 22.234 | -13.88 ± 27.600 |
| % Activity Impairment Week 28 (OL) | -15.91 ± 27.196 | -14.69 ± 32.539 |
The PHQ-9 consists of 9 questions that assess how often over the past 2 weeks subjects had signs or symptoms of depression (0=not at all, 1=several days, 2=more than half days, and 3=nearly every day). The PHQ-9 is the sum of the scores from the 9 questions for a total range from 0 (not depressed at all) to 27 (depressed nearly every day).
| units on a scale | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Week 2 | -2.85 ± 4.332 | -2.86 ± 4.449 |
| Week 8 | -2.43 ± 4.057 | -1.80 ± 4.796 |
| Week 16 | -2.64 ± 6.637 | -2.14 ± 4.659 |
| Week 28 (open-label) | -3.32 ± 5.719 | -2.65 ± 5.031 |
Based on the 9 questions of the PHQ-9, if subjects indicated any problems (PHQ-9 score \> 0), the difficulty to do work, take care of things at home, and get along with people (question 10 of the PHQ) were assessed (not difficult at all, somewhat difficult, very difficult, and extremely difficult).
| subjects | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Not difficult at all - Baseline | 4 | 20 |
| Somewhat difficult - Baseline | 9 | 19 |
| Very difficult - Baseline | 3 | 5 |
| Extremely difficult - Baseline | 7 | 5 |
| Not difficult at all - Week 2 | 5 | 21 |
| Somewhat difficult - Week 2 | 9 | 16 |
| Very difficult - Week 2 | 2 | 3 |
| Extremely difficult - Week 2 | 7 | 9 |
| Not difficult at all - Week 8 | 4 | 18 |
| Somewhat difficult - Week 8 | 8 | 15 |
| Very difficult - Week 8 | 2 | 5 |
| Extremely difficult - Week 8 | 9 | 11 |
| Not difficult at all - Week 16 | 3 | 19 |
| Somewhat difficult - Week 16 | 8 | 10 |
| Very difficult - Week 16 | 2 | 1 |
| Extremely difficult - Week 16 | 10 | 19 |
| Not difficult at all - Week 28 (OL) | 4 | 21 |
| Somewhat difficult - Week 28 (OL) | 5 | 6 |
| Very difficult - Week 28 (OL) | 2 | 1 |
| Extremely difficult - Week 28 (OL) | 12 | 21 |
Collected over All adverse events (AEs) from the time of study drug administration until 70 days following completion (Week 28) or discontinuation of study drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Adalimumab | — | 1/23 (4.3%) | 15/23 (65.2%) |
| Adalimumab | — | 2/49 (4.1%) | 30/49 (61.2%) |
| Event | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/23 | 0/49 |
| Breast massReproductive system and breast disorders | 1/23 | 0/49 |
| Acute myocardial infarctionCardiac disorders | 0/23 | 1/49 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/23 | 1/49 |
| Event | Placebo/Adalimumab | Adalimumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/23 | 13/49 |
| HeadacheNervous system disorders | 1/23 | 7/49 |
| DiarrhoeaGastrointestinal disorders | 3/23 | 1/49 |
| BronchitisInfections and infestations | 3/23 | 1/49 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/23 | 0/49 |
| NauseaGastrointestinal disorders | 2/23 | 0/49 |
| ToothacheGastrointestinal disorders | 2/23 | 0/49 |
| Injection site reactionGeneral disorders | 2/23 | 2/49 |
| Oedema peripheralGeneral disorders | 2/23 | 2/49 |
| Urinary tract infectionInfections and infestations | 2/23 | 0/49 |
| Age Categorical(subjects) | Placebo/Adalimumab | Adalimumab | Total |
|---|---|---|---|
| < 40 years | 1 | 11 | 12 |
| Between 40 and < 60 years | 14 | 29 | 43 |
| >= 60 years | 8 | 9 | 17 |
| Age Continuous(years) | Placebo/Adalimumab | Adalimumab | Total |
|---|---|---|---|
| Mean | 54.8 ± 11.40 | 49.0 ± 11.41 | 50.9 ± 11.65 |
| Sex: Female, Male(Participants) | Placebo/Adalimumab | Adalimumab | Total |
|---|---|---|---|
| Female | 15 | 28 | 43 |
| Male | 8 | 21 | 29 |
| Region of Enrollment(participants) | Placebo/Adalimumab | Adalimumab | Total |
|---|---|---|---|
| United States | 9 | 20 | 29 |
| Canada | 14 | 29 | 43 |
The record gives a start of Aug 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab